{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:48:52Z","timestamp":1785836932901,"version":"3.56.0"},"reference-count":16,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Introduction and Objective<\/jats:title><jats:p>Procedural therapies for overactive bladder (OAB) most often include intradetrusor onabotulinumtoxinA (BTX) injections, sacral neuromodulation (SNM), and percutaneous tibial nerve stimulation (PTNS). Despite their proven efficacy, real\u2010world data on therapy continuation and crossover rates between these modalities remain limited. This study aimed to evaluate longitudinal patterns of treatment continuation and therapy crossover among women receiving procedural OAB treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a multi\u2010institutional retrospective cohort study of women with idiopathic OAB who underwent index BTX, SNM, or PTNS between 2014 and 2022. Patients were identified using electronic medical records, and follow\u2010up data were collected through December 31, 2023. The primary outcomes included duration of maintenance treatments and crossover to another procedural therapy for OAB. Kaplan\u2013Meier survival analysis estimated rates of continued treatment, and a log\u2010rank test assessed differences in crossover rates among treatment groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 506 women met inclusion criteria: 266 (52.6%) received BTX, 114 (22.5%) underwent SNM, and 126 (24.9%) received PTNS. Ongoing treatment rates were lowest for PTNS, with only 17.1% maintaining therapy between 3 and 5 years and 26.1% crossing over to another procedure within 3 years. Among BTX patients, 65.2% underwent repeat treatment within 3 years, and 9.5% of patients crossed over to another procedure within 3 years. Of those with 5 or more years of follow\u2010up, 39.1% of patients continued with BTX procedures in the 3\u20135\u2010year follow\u2010up timeframe. Among SNM patients, the cumulative revision rates were 7.6% at 1 year and 10.9% at 2 years. 13.1% of patients crossed over from SNM to another procedure within 3 years (the vast majority to BTX).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>PTNS had the lowest ongoing therapy rates and the highest crossover rates. BTX and SNM demonstrated similar crossover rates. These findings underscore the importance of individualized patient counseling and treatment selection based on expectations of therapy persistence. Future research should focus on optimizing patient selection, improving long\u2010term adherence strategies, and evaluating novel or combined therapeutic approaches for OAB management.<\/jats:p><\/jats:sec>","DOI":"10.1002\/nau.70088","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T02:58:58Z","timestamp":1749005938000},"page":"1332-1338","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patterns of Care Following Procedural Intervention Among Women With Overactive Bladder"],"prefix":"10.1002","volume":"44","author":[{"given":"Francis A.","family":"Jefferson","sequence":"first","affiliation":[{"name":"Department of Urology Mayo Clinic Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine T.","family":"Hanson","sequence":"additional","affiliation":[{"name":"The Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery Surgical Outcomes Program, Mayo Clinic Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aqsa A.","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Urology Mayo Clinic Scottsdale Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Gebhart","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Mayo Clinic Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Elliott","sequence":"additional","affiliation":[{"name":"Department of Urology Mayo Clinic Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4674-2598","authenticated-orcid":false,"given":"Brian J.","family":"Linder","sequence":"additional","affiliation":[{"name":"Department of Urology Mayo Clinic Rochester Minnesota USA"},{"name":"Department of Obstetrics and Gynecology Mayo Clinic Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-024-06029-2"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/SPV.0000000000001575"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003985"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/SPV.0000000000000744"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins12020128"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-020-04429-8"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.02.011"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/SPV.0000000000001639"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.10.054"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.12.011"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.25370"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.25421"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins15050338"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000003320"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/SPV.0000000000001442"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001950"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.70088","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T03:44:31Z","timestamp":1754538271000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.70088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1002\/nau.70088"],"URL":"https:\/\/doi.org\/10.1002\/nau.70088","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"2025-05-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}